이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Adicet Bio 관리

관리 기준 확인 2/4

Adicet Bio's CEO는 Chen Schor, Sep2020 에 임명되었습니다 의 임기는 4.08 년입니다. 총 연간 보상은 $ 5.97M, 10.1% 로 구성됩니다. 10.1% 급여 및 89.9% 보너스(회사 주식 및 옵션 포함). 는 $ 194.25K 가치에 해당하는 회사 주식의 0.16% 직접 소유합니다. 194.25K. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 3.4 년입니다.

주요 정보

Chen Schor

최고 경영자

US$6.0m

총 보상

CEO 급여 비율	10.1%
CEO 임기	4.1yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chen Schor 의 보수는 Adicet Bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$137m
Mar 31 2024	n/a	n/a	-US$140m
Dec 31 2023	n/a	n/a	-US$143m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$4m	US$562k	-US$70m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$10m	US$536k	-US$62m
Sep 30 2021	n/a	n/a	-US$55m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$11m	US$499k	-US$37m

보상 대 시장: Chen 의 총 보상 ($USD 5.97M )은 UK 시장( $USD 368.02K ).

보상과 수익: 회사가 수익성이 없는 동안 Chen 의 보상이 증가했습니다.

CEO

Chen Schor (52 yo)

4.1yrs

테뉴어

US$5,973,807

보상

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chen Schor	CEO, President & Director	4.1yrs	US$5.97m	0.16% $ 195.6k
Aya Jakobovits	Founder & Independent Director	no data	US$240.29k	1.04% $ 1.2m
Brian Harvey	Chief Financial Officer	4.1yrs	US$2.13m	0.068% $ 81.3k
Donald Healey	Chief Technology Officer	4yrs	US$2.09m	0.043% $ 51.1k
Blake Aftab	Senior VP & Chief Scientific Officer	3.5yrs	US$2.48m	0.031% $ 36.8k
Amy Locke	Chief Human Resource Officer	2.8yrs	데이터 없음	데이터 없음
Francesco Galimi	Chief Medical Officer & Senior VP	4.1yrs	US$1.99m	0.092% $ 109.5k
Nancy Boman	Senior VP & Chief Regulatory Officer	1.9yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 0HX7 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chen Schor	CEO, President & Director	4.1yrs	US$5.97m	0.16% $ 195.6k
Aya Jakobovits	Founder & Independent Director	4.1yrs	US$240.29k	1.04% $ 1.2m
Carl Gordon	Independent Chairman	4.1yrs	US$275.29k	0.0072% $ 8.6k
Steve Dubin	Independent Director	4.1yrs	US$254.29k	0.013% $ 15.8k
Andrew Sinclair	Independent Director	3.6yrs	US$255.29k	0.0072% $ 8.6k
Jeffrey Chodakewitz	Independent Director	4.1yrs	US$240.29k	0.0072% $ 8.6k
Marco Davila	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Lloyd Klickstein	Director	less than a year	US$2.90m	0.12% $ 148.9k
Michael Kalos	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Saul Priceman	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Constantine Mitsiades	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Alice Bertaina	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: 0HX7 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Adicet Bio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Revenue beats expectations

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령